Skip to content

Peripheral artery disease more common in people with HIV with lower CD4 counts

PrEP use in US exceeds 100,000 in Gilead pharmacy survey

Incidence of anal cancer has already peaked among HIV-positive gay men; reductions can be achieved with expanded ART coverage and screening

Treatment with DAAs reduces the risk of mortality in the first 18 months after the completion of treatment

Switch from boosted protease inhibitor to dolutegravir reduces lipids in people with HIV at higher risk of heart disease

Boosted darunavir plus lamivudine matches three-drug regimen

European and US regulators approve AbbVie's new combo for all hepatitis C genotypes

Demand for access to NHS PrEP trial looks set to outstrip places

Demand for access to NHS PrEP trial looks set to outstrip places

PrEP demand in England is rapidly accelerating – and most will want to join the trial

PrEP demand in England is rapidly accelerating – and most will want to join the trial